» Articles » PMID: 10831181

Effect of Tumor Necrosis Factor Alpha and Transforming Growth Factor Beta 1 on Plasminogen Activator Inhibitor-1 Secretion from Subcutaneous and Omental Human Fat Cells in Suspension Culture

Overview
Journal Metabolism
Specialty Endocrinology
Date 2000 Jun 1
PMID 10831181
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Elevated levels of plasminogen activator inhibitor-1 (PAI-1) are characteristic of the obese state and may contribute to the association between obesity and cardiovascular disease. In this study, we measured the rate of secretion of PAI-1 antigen in isolated subcutaneous and omental abdominal adipocytes from severely obese and non-obese individuals and studied the effect of selected cytokines on PAI-1 release using a suspension culture technique. PAI-1 secretion was approximately 2-fold greater in isolated fat cells from the obese versus non-obese subjects. In addition, PAI-1 mRNA levels were higher in adipose tissue samples from obese versus non-obese individuals (P < .05). PAI-1 release was also approximately 2-fold greater in omental versus subcutaneous adipocytes from both obese and non-obese subjects (each P < .05). A 24-hour exposure to 1 nmol/L tumor necrosis factor alpha (TNF-alpha) slightly increased PAI-1 release from both subcutaneous and omental adipocytes (30% +/- 21% and 17% +/- 18%, respectively, nonsignificant [NS]). Transforming growth factor beta 1 (TGF-beta1) induced a significant dose-dependent increase of PAI-1 release into the medium. Exposure to 400 pmol/L TGF-beta1 of subcutaneous and omental fat cells from both obese and non-obese individuals elevated PAI-1 secretion by 2-fold. These data provide evidence that human fat cells release a substantial amount of PAI-1 in a depot-specific manner and that TGF-beta1 particularly contributes to the regulation of PAI-1 secretion.

Citing Articles

Tale of two systems: the intertwining duality of fibrinolysis and lipoprotein metabolism.

Dai W, Castleberry M, Zheng Z J Thromb Haemost. 2023; 21(10):2679-2696.

PMID: 37579878 PMC: 10599797. DOI: 10.1016/j.jtha.2023.08.004.


Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism.

Frischmuth T, Hindberg K, Aukrust P, Ueland T, Braekkan S, Hansen J J Thromb Haemost. 2022; 20(7):1618-1626.

PMID: 35289062 PMC: 9314992. DOI: 10.1111/jth.15701.


TGF-β: The missing link in obesity-associated airway diseases?.

Woo J, Koziol-White C, Panettieri Jr R, Jude J Curr Res Pharmacol Drug Discov. 2021; 2:100016.

PMID: 34909651 PMC: 8663968. DOI: 10.1016/j.crphar.2021.100016.


A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease.

Morrow G, Whyte C, Mutch N Front Cardiovasc Med. 2021; 8:653655.

PMID: 33937363 PMC: 8085275. DOI: 10.3389/fcvm.2021.653655.


Immunohistochemical expression of plasminogen activator inhibitor-1 in subcutaneous versus omental adipose tissue in patients after elective abdominal surgery.

Yildiz M, Bozkurtlar E, Azizy A, Agirbasli M Autops Case Rep. 2019; 9(4):e2019121.

PMID: 31641662 PMC: 6771447. DOI: 10.4322/acr.2019.121.